Trump Is Promising to Lower Drug Prices. Don’t Count on It

Summary

In a move aimed at curbing high prescription drug prices, the Trump administration has unveiled a new executive order, but critics say it doesn't go far enough. While expanding Medicare's negotiation program to cover more expensive drugs like semaglutide is notable, discounts won't start until 2028. The reversal of a Biden-era proposal on weight loss medications and delays in biologics negotiations have raised concerns. Senator Ron Wyden calls the order "weak," arguing it favors pharmaceutical companies and points to FDA cuts and potential tariffs as likely cost drivers. Overall skepticism remains about Trump's ability to significantly lower drug prices during his presidency.

Additional Summaries

prescription drug prices are certain to remain high under President Trump’s proposed plan, despite some promising ideas in his executive order. The focus on improving Medicare negotiate programs may eventually lower costs for some patients like those using semaglutide, but delays and administrative barriers could undermine these efforts. Meanwhile, the broader shift toward cutting drug prices is unlikely to yield significant savings or meaningful reductions for Americans who rely on these medications.